Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Key Points aGVHD causes loss of gastric stem cells, G-cells, and PCs, leading to increased gastric pH. Pentagastrin therapy repairs stem cell and PC deficits, reverses pH changes, and reduces aGVHD damage, improving survival. Abstract Acute graft-versus-host disease (aGVHD) is a…
Patients who receive hematopoietic stem cell transplants are at risk of developing graft-versus-host disease (GVHD), where the immune cells descended from the transplanted stem cells attack the transplant recipient’s own tissues. Acute GVHD (aGVHD) is often treated with…
Myelodysplastic syndromes/neoplasms (MDS) are myeloid malignancies with ineffective hematopoiesis, resulting in variable cytopenias and increased risk of progression to acute myeloid leukemia (AML) [1, 2]. Imetelstat, a first-in-class competitive telomerase inhibitor, is an…
Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current…
Abstract Venetoclax (Ven) in combination with hypomethylating agents (HMA) (azacitidine or decitabine) is the standard of care for elderly or unfit patients with acute myeloid leukemia (AML) and is being explored in high-risk myelodysplastic syndrome (HR-MDS). However, currently…
Abstract Allogeneic hematopoietic cell transplantation (ASCT) is the only curative option for patients with myelodysplastic syndromes (MDS), but whether cytoreductive pretreatment and molecular “downstaging” according to the IPSS-M improves outcomes remains unclear. We…
Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…
Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…
Key Points For patients with AML treated with LIT, ELN 2024 and Beat AML 2024 best identify a favorable group. Allogeneic stem cell transplant improves survival, but patients classified as adverse risk by any system still have poor outcomes. Abstract Real-world validation of the…